Groundbreaking

We are curious, fast and brave. We are scientific experts who want to improve the lives of patients. We rely on our outstanding scientific know-how, our leading antibody technology and novel therapeutic approaches to discover, develop and deliver transformative therapies for people who are impacted by cancer and autoimmune diseases.

Reliable

We are a reliable partner committed to the highest quality in everything we do. We provide top-quality products and services and are dedicated to excellence and safety in all processes of our value chain. We are fully aware that we bear a great responsibility.

Dedicated

We firmly believe that advanced antibody-based therapies are a key to treating cancer and autoimmune diseases. We love science, but even more so, we love helping patients who are impacted by these diseases. Every day we come to work driven to make a difference.

The patient in mind

Being able to help patients, give them hope and provide them with the best treatment available is our strongest motivation. Therefore, everything we do, every product, process, contact and service, needs to be of the highest quality to meet patients’ needs.


20/10/2021
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in...
11/10/2021
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy...
26/08/2021
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(...


MorphoSys
as a Partner

Visit

Company calendar

Date
Title
Add to Calendar
  1. 03/15/2021

    Year-End Results 2020

  2. 05/05/2021

    First Quarter Interim Statement 2021

  3. 05/19/2021

    Annual General Meeting 2021

  4. 07/28/2021

    Half-Year Report 2021

  5. 11/10/2021

    Third Quarter Interim Statement 2021

Upcoming conferences

Wed
10
'21
Nov

Third Quarter Interim Statement 2021

Thu-Tue
09-14
'21
Dec
Dec

American Society of Hematology

Atlanta, Georgia, USA

Stock information